FBLG - שווי פעילות לרווח לפני ריבית, מסים ופחת FibroBiologics

This EV/EBITDA chart, which currently stands at 0.00, is based on the application of unique cellular technologies to combat disc degeneration and sclerosis. This price action is supported by the recruitment of leading biologists and the retention of R&D personnel through stock options. Consequently, FibroBiologics, Inc. (FBLG) is leveraging the expansion of its patent portfolio to secure a dominant position in the regenerative medicine sector.

The EV/EBITDA multiple determines the total value of a business relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of real capital regardless of the financing structure. By analyzing the EV/EBITDA metric inclusive of depreciation and debt, investors determine the fair value of FibroBiologics, Inc. (FBLG) assets, taking into account the extensive expenditures on the patent portfolio required for the subsequent global scaling of cellular technologies.